Of these four patients, one patient received PEG‐ASP through the end of interim maintenance but did not continue further due to recurrent hyperbilirubinemia, one patient received PEG‐ASP through the end of delayed intensification, one received PEG‐ASP with all courses of RD‐10403 leading up to allo‐HCT, and one patient did not receive additional PEG‐ASP due to anaphylaxis during consolidation and was switched to Erwinia asparaginase for subsequent doses. The gene discussed is ASPG; the disease is anaphylaxis.